公开(公告)号：US20230416268A1

公开(公告)日：2023-12-28

申请号：US18139506

申请日：2023-04-26

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yat Sun Or ,  Joseph D. Panarese ,  Guoqiang Wang ,  Jing He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Sourav Ghorai

IPC: C07D495/04

CPC classification number: C07D495/04

Abstract: The present invention provides compounds of Formula (I),




pharmaceutical compositions comprising these compounds and methods of using these compounds for treating a metabolic disease or liver condition. The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.

公开(公告)号：US20230159546A1

公开(公告)日：2023-05-25

申请号：US17989103

申请日：2022-11-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jorden Kass ,  Wei Li ,  Hui Cao ,  Jiajun Zhang ,  Xuri Gao ,  Xiaowen Peng ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10

CPC classification number: C07D487/10

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230159545A1

公开(公告)日：2023-05-25

申请号：US17983484

申请日：2022-11-09

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Joseph D. Panarese ,  Samuel Bartlett ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  C07D519/00

CPC classification number: C07D487/10 ,  C07D519/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230115107A1

公开(公告)日：2023-04-13

申请号：US17720654

申请日：2022-04-14

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Xuri Gao ,  Wei Li ,  Jiajun Zhang ,  Xiaowen Peng ,  Hui Cao ,  Jorden Kass ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  C07D487/12 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11555032B2

公开(公告)日：2023-01-17

申请号：US16871551

申请日：2020-05-11

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Jun Ma ,  Bin Wang ,  Ruichao Shen ,  Xuechao Xing ,  Yong He ,  Yat Sun Or

IPC: C07D417/12 ,  C07D413/12 ,  C07D417/14 ,  C07D261/08 ,  C07D413/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US11420976B2

公开(公告)日：2022-08-23

申请号：US17155159

申请日：2021-01-22

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yong He ,  Xuechao Xing ,  Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jiang Long ,  Yat Sun Or

IPC: C07D491/048 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20220162231A1

公开(公告)日：2022-05-26

申请号：US17531844

申请日：2021-11-22

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jun Ma ,  Yong He ,  Xuechao Xing ,  Hui Cao ,  Xuri Gao ,  Xiaowen Peng ,  Joseph D. Panarese ,  Yat Sun Or

IPC: C07D519/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220119398A1

公开(公告)日：2022-04-21

申请号：US17503626

申请日：2021-10-18

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yat Sun Or ,  Yong He ,  Kevin McGrath ,  Ruichao Shen ,  Adam Szymaniak ,  Xuechao Xing ,  In Jong Kim ,  Guoqiang Wang

IPC: C07D491/048 ,  A61P31/14 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20210261600A1

公开(公告)日：2021-08-26

申请号：US17186447

申请日：2021-02-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Jiang Long ,  Peng Dai ,  Xuechao Xing ,  Jing He

IPC: C07J41/00 ,  C07J43/00

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10968249B2

公开(公告)日：2021-04-06

申请号：US16878329

申请日：2020-05-19

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Jiang Long ,  Peng Dai ,  Xuechao Xing ,  Jing He

IPC: C07J41/00 ,  C07J43/00 ,  C07J9/00 ,  C07J51/00

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.